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Background
The anti- IL-6 Receptor monoclonal antibody Tocilizu-
mab (TCZ) has demonstrated its efficacy in Japanese
children with systemic onset juvenile idiopathic arthritis
(SJIA).
Aim
To evaluate the efficacy and safety of TCZ in European
patients with active SJIA outside a clinical trial (off-label
use).
Patients and methods
Retrospective review of the files of the patients treated
by TCZ in two French, one Swiss and one Italian center.
Response to treatment was defined as control of the
fever and systemic features for at least 7 days, Improve-
ment of the pediatric ACR score and normalization of
erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP) were also considered.
Results
18 patients aged 4-15 years were included. The median
disease duration at treatment onset was 4.7 years (0.4-
8.8). The median dose of prednisone at TCZ onset was
0.63mg/kg/d. Four patients were also on MTX. Fourteen
patients had previously failed to respond one or several
biologics, including anti-TNF alpha in 10 cases, anakinra
in 14 and canakinumab, in 4. All patients but 4 had
active systemic and polyarticular features at TCZ onset.
The doses of TCZ ranged between 6 and 12 mg/kg
every other week at treatment onset. The mean follow-
up on TCZ was 18.2 months (range0.5-48). 90%
improvement of the pediatric ACR score was achieved
by 9 patients after 3 months. The dose of steroids was
tapered in most cases (11/14) within 3 months, and five
patients could discontinue steroid treatment after 12
months. TCZ treatment was withdrawn in 5 children
for adverse events: anaphylactic reaction in 3 cases, skin
vasculitis in 2 other cases.
Conclusion
In this study TCZ treatment was effective in most
patients with SJIA who previously failed one or several
biologics. Adverse events require particular attention
since almost one third of patients had to discontinue
treatment.
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